Physician profile
Rookmini Singh
NPI 1912475377
$1,755.52
in general payments reported to CMS, 2019-2025
19 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $158 · 2022: $213 · 2023: $507 · 2024: $417 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,302 · Education: $82.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,301.54 |
| Education | $82.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $520.76 | 2021-2025 | |
| Incyte Corporation | $282.89 | 2021-2023 | |
| Sobi, INC | $224.87 | 2023-2025 | |
| Daiichi Sankyo INC. | $124.26 | 2023-2025 | Vanflyta |
| Takeda Pharmaceuticals U.S.A., INC. | $92.45 | 2023-2025 | Iclusig, Ninlaro |
| Servier Pharmaceuticals LLC | $80.54 | 2023-2024 | |
| Pfizer INC. | $73.92 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $58.56 | 2023-2024 | |
| Glaxosmithkline, LLC. | $56.33 | 2024-2025 | Ojjaara |
| Azurity Pharmaceuticals, INC. | $34.26 | 2025 | Danziten |
| Astellas Pharma US INC | $30.67 | 2025 | Cresemba |
| Rigel Pharmaceuticals, INC. | $29.22 | 2023 | Rezlidhia, Tavalisse |
| Blueprint Medicines Corporation | $26.04 | 2024 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $25.47 | 2025 | Ultomiris |
| Genzyme Corporation | $22.08 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $21.53 | 2021 | |
| Taiho Oncology, INC. | $19.09 | 2021 | |
| Cti Biopharma Corp. | $17.03 | 2023 | Vonjo |
| Genentech USA, INC. | $15.55 | 2024 | Venclexta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rookmini Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.